Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VSV-IFNβ-NIS Monotherapy and with Avelumab in Refractory Solid Tumors
NCT02923466Phase 1Completed
- Sponsor
- Vyriad
- Start
- Apr 2017
- Primary completion
- Feb 2022
- Modality
- Oncolytic Viruses
- Countries
- 1
01
Overview
Phase 1, open-label trial of Voyager-V1 in solid tumor, colorectal cancer (CRC), pheochromocytoma and 3 more (3 arms), sponsored by Vyriad. Primary endpoint: Maximum Tolerated Dose at 21 days. Started Apr 2017; status: completed.
02
Drugs
Voyager-V1
03
Conditions
solid tumorcolorectal cancer (CRC)pheochromocytomaNeuroendocrine Neoplasm (NEN)melanoma
Beyond the preview
Go deeper on NCT02923466.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02923466.